1.12422

N-Acetyl-L-cysteine

for biochemistry

Manufacturer: Millipore

CAS Number: 616-91-1

Synonym(S): N-Acetyl-L-cysteine, 2-Acetamido-3-mercaptopropionic acid

Select a Size

Pack Size SKU Availability Price
25 G 1.12422-25-G In Stock ₹ 5,600.00
100 G 1.12422-100-G In Stock ₹ 23,010.00
1 KG 1.12422-1-KG In Stock ₹ 1,08,960.00

1.12422 - 25 G

₹ 5,600.00

In Stock

Quantity

1

Base Price: ₹ 5,600.00

GST (18%): ₹ 1,008.00

Total Price: ₹ 6,608.00

vapor pressure

<1 hPa ( 20 °C)

Quality Level

100

form

solid

potency

5050 mg/kg LD50, oral (Rat)

pH

1.5-2.5 (20 °C, 100 g/L in H2O)

mp

110.4 °C

solubility

179.5 g/L

density

1.48 g/cm3 at 20 °C

bulk density

730 kg/m3

storage temp.

2-30°C

Related Products

Img

Millipore

1.01543

for biochemistry...

Img

Millipore

1.07434

for biochemistry...

Img

Millipore

1.05707

for biochemistry...

Img

Millipore

1.02838

for biochemistry...

Img

Millipore

1.04350

for biochemistry...

Img

Millipore

1.08371

for biochemistry...

Img

Millipore

1.02839

for biochemistry...

Img

Millipore

1.01007

for biochemistry...

Description

  • Application: Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis: This study presents a novel N-Acetyl-L-cysteine application in aerosol form designed to treat Pseudomonas aeruginosa biofilm infections in cystic fibrosis patients, highlighting its potential to improve pulmonary function and reduce bacterial colonization (Alhajj et al., 2024).Emetine induces oxidative stress, cell differentiation and NF-κB inhibition, suppressing AML stem/progenitor cells: Research indicates that N-Acetyl-L-cysteine, as part of a combinatory therapy, enhances the oxidative stress response in acute myeloid leukemia, providing a therapeutic strategy for targeting leukemia stem cells (Silva et al., 2024).N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses: This meta-analysis reveals N-Acetyl-L-cysteine′s effectiveness in reducing exacerbations and improving antioxidant defense in COPD and chronic bronchitis, suggesting a significant therapeutic benefit in respiratory disease management (Papi et al., 2024).Tannic acid- and N-acetylcysteine-chitosan-modified magnetic nanoparticles reduce hepatic oxidative stress in prediabetic rats: N-Acetyl-L-cysteine, used in modifying magnetic nanoparticles, shows promising results in reducing oxidative stress and liver damage in a prediabetic rat model, underscoring its potential in preventive therapies (Świętek et al., 2024).Phenylarsine oxide induced corneal injury involves oxidative stress mediated unfolded protein response and ferroptotic cell death: Amelioration by NAC: This research outlines N-Acetyl-L-cysteine′s role in mitigating oxidative stress and ferroptosis in corneal cells, providing insights into its protective effects against chemical-induced ocular damage (Kandhari et al., 2023).
  • Analysis Note: Assay (iodometric): ≥ 99.0 %Identity (IR-spectrum): passes testAppearance: white to almost white, crystalline powder or colorless crystalsAppearance of solution (1 mol/l, water): clear and colorlessSpec. rotation (α 20/D, 50 g/l, buffer pH 7.0): +21.0 to +27.0Heavy metals (as Pb): ≤ 0.001 %NH₄ (Ammonium): ≤ 0.01 %L-cysteine (HPLC): ≤ 0.02 %Other ninhydrine positive substances: ≤ 0.1 %

SAFETY INFORMATION

Pictograms

GHS07

Signal Word

Warning

Hazard Statements

H319

Precautionary Statements

P264 - P280 - P305 + P351 + P338 - P337 + P313

Hazard Classifications

Eye Irrit. 2

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable